Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Biotechnology
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Even Goodman's charity ... designed for long-term success
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Post by MrMugsyon Apr 07, 2022 8:44am
176 Views
Post# 34583555

Even Goodman's charity ... designed for long-term success

Even Goodman's charity ... designed for long-term successAs executive chair of Knight Therapeutics, which markets and licenses drugs from international drugmakers for Canada and Latin America, Goodman is still deeply involved in the world of pharmaceuticals and remains dedicated to helping others through his philanthropy. “Ironically, selling drugs pays for my tzedakah habit,” he jokes. 

https://www.jpost.com/israel-news/article-703509


On a more serious note, he adds that the word “recovery” is not the right term for a traumatic brain injury. “I will never recover, and I will never be who I was. But I am smart enough and driven enough to make a difference in this world.”
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities